Via Pharmaceuticals Inc · OTC:VIAP
Via Pharmaceuticals — Investor Presentation (August 2007)
32 slides from Via Pharmaceuticals's investor presentation, Aug 15, 2007
Slide 1: VIA Pharmaceuticals Presentation
VIA Pharmaceuticals VIA Pharmaceuticals Presentation Presentation August 2007 Exhibit 99.1
Slide 2: Safe Harbor
SAFE HARBOR SAFE HARBOR This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other fac
Slide 3: VIA Investment Highlights
VIA Investment Highlights VIA Investment Highlights Late stage Phase II company with focus on inflammation in atherosclerosis • Phase II DSMB Safety / Efficacy – Q4 2007 • Phase II data expected – st half 2008 Proprietary technology platform licensed from Stanford creating strong product pipeline Pr
Slide 4: Focus on Vascular Inflammation in Atherosclerosis
Focus on Vascular Inflammation Focus on Vascular Inflammation in Atherosclerosis in Atherosclerosis
Slide 5: Inflammation is Key in Atherosclerosis
Inflammation is Key in Atherosclerosis Inflammation is Key in Atherosclerosis VIA proprietary data suggests that reduction in inflammation will reduce Major Adverse Cardiac Events (MACE) Convergent data underscores the role inflammation plays in MACE Site of intimal rupture or erosion of thrombosed
Slide 6: Atherosclerosis is VIA's Area of Focus
MACE Healthy artery Early stages of atherosclerosis Inflammatory process Early atherosclerotic lesions Vulnerable plaque Stable plaque CHD RISK STARTS HERE CHD STARTS HERE Atherosclerosis is VIA’s Atherosclerosis is VIA’s Area of Focus Area of Focus Inflammation is a key to all stages of the disease
Slide 7: Leukotrienes Mediate Vascular Inflammation
Leukotrienes Mediate Vascular Inflammation 5-LO is the rate limiting enzyme • Inhibition is therapeutic in asthma VIA identified 5-LO as target for atherosclerosis • Human genetic data implicates 5-LO in MACE • Expression data in mouse and man shows increased expression in disease • Inhibition of 5-
Slide 8: VIA is in Late Stage Clinical Trials
VIA is in Late Stage Clinical Trials VIA is in Late Stage Clinical Trials
Slide 9: Late Stage Clinical Development Plan
Late Stage Clinical Development Plan Late Stage Clinical Development Plan DSMB Review Safety / Efficacy
Slide 10: First VIA Drug is 5-LO Inhibitor
First VIA Drug is 5-LO Inhibitor First VIA Drug is 5-LO Inhibitor Strong product characteristics • ABT-761 Atreleuton VIA-2291 • Once daily oral dosing • Highly specific • Potential for greater therapeutic index Extensive clinical experience – more than 1,100 patients exposed • 20 Phase I studies, 6
Slide 11: Significant Human Data on VIA-2291
Significant Human Data on VIA-2291 Significant Human Data on VIA-2291 VIA-2291 Dose versus % LTB4 Inhibition Human data from Abbott 1100 patients showing the effective inhibition of LTB4 at multiple doses Time (hours) 25 mg 50 mg 75 mg 100 mg
Slide 12: Strong VIA Clinical Trial Design
Strong VIA Clinical Trial Design Strong VIA Clinical Trial Design Robust animal and human data for VIA-2291 Integration of histology, imaging and biomarker endpoints Demonstrate direct impact on disease process State of the art design - FDA “ Critical Path ” initiative
Slide 13: Ongoing VIA-2291 Clinical Trials - CEA
Ongoing VIA-2291 Clinical Trials - Ongoing VIA-2291 Clinical Trials - CEA CEA Trial Phase II CEA Population Carotid artery disease Carotid Endarterectomy Description 40 patients scheduled for CEA Randomized, double-blind 3 months 100mg/day or placebo pre-surgery Endpoints Inhibition of 5-LO Inflamma
Slide 14: Ongoing VIA-2291 Clinical Trials - ACS
Ongoing VIA-2291 Clinical Trials - Ongoing VIA-2291 Clinical Trials - ACS ACS Trial Phase II ACS Population Coronary artery disease Acute Coronary Syndrome Description 200 patients within 21 days of heart attack Randomized, double-blind 3 months 25mg/day, 50 mg/day, 100 mg/day or placebo Endpoints I
Slide 15: Strong VIA-2291 Patent Coverage
Strong VIA-2291 Patent Coverage Strong VIA-2291 Patent Coverage Issued US Patent • Composition of Matter • Discloses and claims VIA-2291 as a species and genus and claims pharmaceutical compositions containing VIA-2291 • Expires: November 6, 2012 (US); November 6, 2013 (major EU markets) Patent Exte
Slide 16: Vascular Inflammation Targets Large Markets
Vascular Inflammation Targets Vascular Inflammation Targets Large Markets Large Markets
Slide 17: Significant Drug Costs
Significant Drug Costs Significant Drug Costs Cholesterol Hypertension Anti-Thrombotics Other 15.8 million cases in US and 1.4 million at “high risk” Current therapies treat only risk factors AHA estimates 700,000 first time and 500,000 recurrent heart attacks in 2007 $26.2 B $ 27.2 B $10.5 B $5.2 B
Slide 18: Large Unmet Medical Need
Large Unmet Medical Need Large Unmet Medical Need 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% IDEAL Prove IT HPS 4S LIPID CARE CAPRIE Risk not addressed Reduction in MACE Lipitor Zocor Pravachol Published Results Plavix
Slide 19: Strong Focus on Product Pipeline
Strong Focus on Product Pipeline Strong Focus on Product Pipeline
Slide 20: Broad Development Pipeline
Broad Development Pipeline Broad Development Pipeline Compound/Target Applications Research Pre-Clinical Phase I Phase II Phase III NDA VIA-2291 / 5-LO Acute Coronary Syndrome CEA PDE 4 Vascular Inflammation LTA4 Hydrolase Vascular Inflammation Novel Targets Vascular Inflammation
Slide 21: VIA Proprietary Technology Platform
VIA Proprietary Technology Platform VIA Proprietary Technology Platform 4 year, $30 million study at Stanford headed by VIA Founder/CSO • Inflammation key in human atherosclerosis • Extensive data from work in mouse model confirms human findings • >3,000 patient study confirms inflammatory genes in
Slide 22: Broad Pool of Anti Inflammatory Compounds
Broad Pool of Anti Inflammatory Compounds Broad Pool of Anti Inflammatory Compounds Qualified Targets Anti inflammatory Compounds Identified Opportunities Preclinical Clinical Stage LOs (5-LO, 12-LO, FLAP) Leukotrienes (LTA4, LTB4, LTC4, LTD4) PPARs PDEs (mostly PDE4) Chemokines, cytokines Phospholi
Slide 23: Data Shows 35% Reduction in Inflammation
Data Shows 35% Reduction in Inflammation Data Shows 35% Reduction in Inflammation * * Reduction in mouse model plaque macrophage with VIA-2291 * p < 0.05
Slide 24: Significant Progress
Significant Progress Significant Progress
Slide 25: Completed Stock Offering
Company: VIA Pharmaceuticals, Inc. Ticker: NASDAQ - VIAP Amount: $25 Million Security: Unregistered Common Stock – PIPE Use of Proceeds: Working Capital and General Corporate Purposes Closing: July 2, 2007 1 st Close August 8, 2007 2 nd Close Completed Stock Offering
Slide 26: Milestones and Drivers of Value
Milestones and Drivers of Value Milestones and Drivers of Value Q1: License from Stanford Q3: Licensed VIA-2291 Q1: IND Filed for VIA-2291 Q3: Initiate Ph II for VIA-2291 Late 2007: VIA-2291 Ph II DSMB Safety / Efficacy Early 2008: Ph II Results for VIA-2291 Development and Operations Series A Finan
Slide 27: Financial Update
Financial Update Financial Update Cash balance • Approximately $8 million at close of merger (net of costs) • Approximately $31 million after PIPE closing Cash burn – approx $1.6 - $1.7million / month at present Total common shares outstanding 19.7 million Fully diluted shares outstanding 21.0 milli
Slide 28: VIA Value Proposition
VIA Value Proposition VIA Value Proposition Low risk drug development platform Strong and building pipeline Scalable business model with significant leverage Strong value proposition for potential partners Attractive valuation
Slide 29: Experienced Management Team
Position Personnel Experience CEO Larry Cohen, PhD Zymoyx, Progenitor, Somatix, Therion CMO Oye Olukotun, MD, MPH Bristol Myers Squibb, Mallinckrodt, Esperion CSO Tom Quertermous, MD Dept Cardiovascular Medicine, Stanford Medical School CDO Mike Perry, DVM, PhD Baxter, Novartis, Schering-Plough SVP
Slide 30: World Class Advisors
World Class Advisors World Class Advisors Scientific Advisors Israel Charo, MD, PhD Assoc. Dir, Gladstone Institute of Cardiovascular Disease, UCSF Christopher Glass, MD, PhD Professor, Cellular and Molecular Medicine, UCSD Colin Funk, PhD Professor, Biochemistry and Physiology, Queens University Ga
Slide 31: VIA Investment Highlights
VIA Investment Highlights VIA Investment Highlights Late stage Phase II company with focus on inflammation in atherosclerosis • Phase II DSMB Safety / Efficacy – Q4 2007 • Phase II data expected – st half 2008 Proprietary technology platform licensed from Stanford creating strong product pipeline Pr
Slide 32: VIA
VIA
VIA Pharmaceuticals — Investor Presentation (August 2007) on 6ix